Why Dow Gained 1,200 Points, Nasdaq 4.35%
U.S. tariff rates on China are relative. At the height of the tariff trade war, the U.S. and China kept escalating tariff rates. At the peak, China faced 145% in tariffs.Over the weekend, the two countries agreed to temporarily lower tariff rates. Chinese import tariffs will fall from 145% to 30%, while China will impose tariffs of 10%, down from 125%. In response to the 90-day agreement, the Dow Jones added 1,160.72 points (+2.81%). Nasdaq gained 4.35%, and the iShares Russell 2000 (IWM) gained 3.52%. The U.S. dollar ended its slump, gaining 1.41%. More importantly, the 10-year Treasury Bond ETF yield (IEF) was 4.471%. The peak yield was on January 13 at around 4.8%. Investors sold safe-haven assets, including bonds. Tobacco stocks fell on the day. Altria (MO), Philip Morris International (PM), and British American Tobacco (BTI) fell on Monday.Speculators rushed back to the magnificent seven stocks. Tesla (TSLA), despite quarterly slumping sales and falling profits, gained 6.75%. Amazon (AMZN) gained even more, adding 8.07% on the day. Meta Platforms (META) increased by nearly 8%. Amazon rose the e-commerce platform needs less expensive Chinese goods to grow sales. Meta performed well on expectations that Alibaba (BABA), JD.com (JD), and PDD’s (PDD) Temu would resume their advertising spending on the platform.The tariff tailwind that hurt stocks is now over, at least for the next 90 days.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


